|Bid||0.0500 x N/A|
|Ask||0.0550 x N/A|
|Day's Range||0.0500 - 0.0500|
|52 Week Range||0.0450 - 0.1900|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").
Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that it anticipates being late in filing its audited annual financial statements (the "Annual Financial Statements") and related management discussion and analysis ("MD&A") for the year ended April 30, 2021, by the prescribed deadline of August 30, 2021, and its interim financial statements (the "Interim Financial Statements") and related MD&A for the interim period ended July 31, 2021, by the prescribed deadline o
Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that Dr. Winston De La Haye, Medical Director of the Aion International Center for Psychedelic Psychiatry in Jamaica (the "Center"), will be speaking at the international CanEx Psychedelics Summit in Montego Bay, Jamaica, taking place July 15 - 16, 2021.